検索結果

ctivitis, based on a compound licensed from Tanabe Pharma Corporation. Allergic conjunctivitis, the target indication of SJP-0049, is an inflammatory disease of the conjunctiva mainly mediated by Type...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

administration trial demonstrated positive results confirming the safety of clinical use. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of Avarept®, is defined as “A multifactorial disease characterized by an unstable tea...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of Avarept®, is defined as “A multifactorial disease characterized by an unstable tea...